ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2466

Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Abstract Number: 1608

Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1963

Efficacy of Apremilast in Patients With Psoriatic Arthritis and Pre-existing Dactylitis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
Abstract Number: 1364

Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Abstract Number: 1222

Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Abstract Number: 2288

Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Abstract Number: 1323

Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
Abstract Number: 1138

Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Abstract Number: 0487

Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Abstract Number: 0599

Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1361

Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Abstract Number: 0398

Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 0557

Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Abstract Number: 2353

Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Abstract Number: 1896

Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].